| چکیده انگلیسی مقاله |
Evaluation and monitoring of pemphigus vulgaris (PV) typically involve autoantibody detection by enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (IIF). We aimed to determine the levels of antipemphigus immunoglobulin (Ig) G autoantibodies using ELISA and IIF (as standard biomarkers), and compare it to prolactin, macrophage migration inhibitory factor (MIF), and C-reactive protein (CRP) (as nonstandard biomarkers) to determine which of these non-standard biomarkers is appropriate for PV monitoring. The experiment was performed before and during therapy. Anti-Dsg immunoglobulin G autoantibodies were measured using ELISA and IIF (as standard biomarkers) versus prolactin, MIF, and CRP (nonstandard), before 1 and 3 months after the treatment. Before beginning the treatment, the severity of the disease was determined using the pemphigus disease area Index (PDAI). We enrolled 60 newly diagnosed patients with PV (32 men and 28 women; mean age=43.8±14.2 years). Before treatment, the levels of anti-Dsg1, anti-Dsg3, and IIF were high and had a significant relationship with PDAI. PDAI also had a connection with the levels of CRP and prolactin. The anti-Dsg1, anti-Dsg3, IIF, and CRP titers decreased in patients treated with conventional (prednisolone plus azathioprine) and rituximab therapy during and after treatment. In conclusion, anti-Dsg1, anti-Dsg3, and IIF autoantibody titers remain standard biomarkers for assessing disease activity, severity, and PV monitoring. The trend of CRP was similar to that of anti-Dsg1, anti-Dsg3, and IIF. Thus, CRP may be used for PV monitoring. |
| نویسندگان مقاله |
| Hossein Mortazavi
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
| Vahide Saeidi
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
| Kamran Balighi
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
| Nafiseh Esmaeili
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran AND Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
| Amir Teimourpour
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| Maryam Daneshpazhooh
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran AND Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
| Shahin Hamzelou
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran AND Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
| Zahra Saffarian
Department of Dermatology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
| Jafar Taghizadeh Fazli
Department of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
|